Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma

Melanoma Research

Volumn 7, Issue 3, 1997, Pages 197-208

  Miller, J G ^a   Gee, J ^b   Price, A ^a   Garbe, C ^c   Wagner, M ^a   Mac Neil, S ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Adhesion molecules; Melanoma; Oestrogen receptors; Sex steroids

Indexed keywords

ANDROSTENEDIONE; CELL ADHESION MOLECULE; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; INTERCELLULAR ADHESION MOLECULE 1; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030844696     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199706000-00003     Document Type: Article

References (37)

1. Vossaert KA, Silverman MK, Kopf AW, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992; 26: 429-440.
2. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 1994; 129: 316-324.
3. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75: 2484-2491.
4. Shaw HM, McGovern VJ, Milton GW, et al. Malignant melanoma: influence of site of lesion and age of patient in the female superiority in survival. Cancer 1980; 46: 2731-2735.
5. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.
6. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343: 913.
7. Duncan LM, Travers RL, Koerner FC, et al. Oestrogen and progesterone receptor analysis in pregnancy-associated melanoma, absence of immunohistochemically detectable hormone receptors. Hum Pathol 1994; 25: 36-41.
8. Cohen C, De Rose PB, Camphell WG, et al. Oestrogen receptor status in malignant melanoma. Am J Dermatopathol 1990; 12: 562-564.
9. Piantelli M, Maggian N, Ricci R, et al. Tamoxifen and Quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol 1995; 105: 248-253.
10. Walker MJ, Beattie CW, Patel MK, et al. Oestrogen receptor in malignant melanoma. J Clin Oncol 1987; 5: 1256-1261.
11. McClay EF, McClay ME. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 1994; 12: 617-626.
12. Banks RE, Gearing AJH, Hemingway IK, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), E-Selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 1993; 68: 122-124.
13. McNcer G, Das Gupta T. Prognosis in malignant melanoma. Surgery 1964; 56: 512.
14. Snead DRJ, Bell JA, Dixon AR, et al. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology 1993; 23: 233-238.
15. Weterman MAJ, van Muijen GNP, Bloemers HPJ, et al. Molecular markers of melanocytic tumour progression. Lab Invest 1994; 70: 593-608.
16. 3 subunit with tumour progression. Cancer Res 1990; 50: 6757-6764.
17. Si Z, Hersey P. Immunohistological examination of the relationship between metastatic potential and expression of adhesion molecules and 'selectins' on melanoma cells. Pathology 1994; 26: 6-15.
18. Harning R, Mainolfi E, Bystryn J-C, et al. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 1991; 51: 5003-5005.
19. Altomonte M, Colizzi F, Esposito G, et al. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 1992; 327: 959.
20. Schadendorf D, Heidel J, Gawlik C, et al. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995; 87: 366-371.
21. Kagashita T, Yoshii A, Kimura T, et al. Analysis of expression and soluble form of intercellular adhesion molecule-1 in malignant melanoma. J Dermatol 1992; 19: 836-840.
22. Pandolfi F, Trentin L, Boyle LA, et al. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumour-infiltrating lymphocytes. Cancer 1992; 69: 1165-1173.
23. Denton KJ, Stretch JR, Gatter KC, et al. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 1992; 167: 187-191.
24. Edward M. Integrins and other adhesion molecules involved in melanocytic tumour progression. Curr Opin Oncol 1995; 7: 185-191.
25. Johnson JP. Identification of molecules associated with the development of metastasis in human malignant melanoma. Infusion Metastasis 1994; 14: 123-130.
26. Kagashita T, Yoshii A, Kimura T, et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer 1993; 53: 4927-4932.
27. Cascinelli N, Morabito A, Bufalino R, et al. Prognosis of stage I melanoma of the skin. Int J Cancer 1980; 26: 733-739.
28. Reintgen DS, Paull DE, Seigler HF, et al. Sex related survival differences in instances of melanoma. Surg Gynecol Obstet 1984; 159: 367-372.
29. O'Doherty CJ, Prescott RJ, White H, et al. Sex differences in presentation of cutaneous malignant melanoma and in survival from stage I disease. Cancer 1986; 58: 788-792.
30. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005.
31. Karakousis CP, Driscoll DL. Prognostic parameters in localised melanoma: gender versus anatomical location. Eur J Cancer 1995; 31: 320-324.
32. Shaw HM, McGovern VJ, Milton GW, et al. Histologic features of tumours and the female superiority in survival from malignant melanoma. Cancer 1980; 45: 1604-1608.
33. Gow SM, Turner EI, Glasier A. The clinical biochemistry of the menopause and hormone replacement therapy. Ann Clin Biochem 1994; 31: 509-528.
34. Rosner W, Hryb DJ, Khan MS, et al. Sex hormone-binding globulin: anatomy and physiology of a new regulatory system. J Steroid Biochem Mol Biol 1991; 40: 813-820.
35. Moore JW, Bulbrook RD. The epidemiology and function of sex hormone-binding globulin. Oxford Rev Reprod Biol 1988; 10: 181-236.
36. Cuzick J, Allen D, Baum M, et al. Long term effects of tamoxifen. Biological Effects of Tamoxifen Working Party. Eur J Cancer 1992; 29A: 15-21.
37. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nature 1996; 2: 381-385.